Ghent University Academic Bibliography

Advanced

Antitumour efficacy of two paclitaxel formulations for hyperthermic intraperitoneal chemotherapy (HIPEC) in an in vivo rat model

Wim Bouquet-Geerardyn UGent, Steven Deleye UGent, Steven Staelens UGent, Lieselotte De Smet UGent, Nancy Van Damme UGent, Isabelle Debergh UGent, Wim Ceelen UGent, Filip De Vos UGent, Jean Paul Remon UGent and Chris Vervaet UGent (2011) PHARMACEUTICAL RESEARCH. 28(7). p.1653-1660
abstract
To evaluate the tumour growth delay of a peritoneal carcinomatosis (PC) of colorectal origin after intraperitoneal chemotherapy with paclitaxel/randomly-methylated-beta-cyclodextrin (Pac/RAME-beta-CD) versus TaxolA (R) at normo- and hyperthermic conditions in rats. Hyperthermic intraperitoneal chemotherapy (HIPEC) was performed 7 days post implantation of the tumour with both formulations at a Pac concentration of 0.24 mg/ml. Tumour evaluation was performed via positron emission tomography (PET) and magnetic resonance imaging (MRI) imaging, measuring tumour activity and tumour volume, respectively. Scans were taken at 2 and 7 days post treatment. PET and MRI data showed a significant reduction in tumour activity and tumour volume for rats treated with Pac/RAME-beta-CD (at normo- and hyperthermic conditions), compared to the control group. Treatment with TaxolA (R) did not result in a significant reduction of tumour activity and tumour volume. No significant differences between the normo- and hyperthermic conditions were observed for both formulations, indicating that hyperthermia and paclitaxel were not synergistic despite the direct cytotoxic effect of hyperthermia. Monitoring tumour growth via PET and MRI indicated that Pac/RAME-beta-CD inclusion complexes had a significantly higher efficacy compared to TaxolA (R) in a rat model for peritoneal carcinomatosis.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
paclitaxel, hyperthermic intraperitoneal chemotherapy, tumour growth delay, beta-cyclodextrin, PERITONEAL CARCINOMATOSIS, CYTOREDUCTIVE SURGERY, OVARIAN-CANCER, COLORECTAL-CANCER, CREMOPHOR EL, CYCLODEXTRIN COMPLEXES, SYSTEMIC CHEMOTHERAPY, THERMAL ENHANCEMENT, RANDOMIZED-TRIAL, DRUG-DELIVERY
journal title
PHARMACEUTICAL RESEARCH
Pharm. Res.
volume
28
issue
7
pages
1653 - 1660
Web of Science type
Article
Web of Science id
000291357700018
JCR category
PHARMACOLOGY & PHARMACY
JCR impact factor
4.093 (2011)
JCR rank
42/259 (2011)
JCR quartile
1 (2011)
ISSN
0724-8741
DOI
10.1007/s11095-011-0401-1
project
Ghent researchers on unfolded proteins in inflammatory disease (GROUP-ID)
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
2016386
handle
http://hdl.handle.net/1854/LU-2016386
date created
2012-02-02 15:16:33
date last changed
2013-02-27 09:09:26
@article{2016386,
  abstract     = {To evaluate the tumour growth delay of a peritoneal carcinomatosis (PC) of colorectal origin after intraperitoneal chemotherapy with paclitaxel/randomly-methylated-beta-cyclodextrin (Pac/RAME-beta-CD) versus TaxolA (R) at normo- and hyperthermic conditions in rats. 
Hyperthermic intraperitoneal chemotherapy (HIPEC) was performed 7 days post implantation of the tumour with both formulations at a Pac concentration of 0.24 mg/ml. Tumour evaluation was performed via positron emission tomography (PET) and magnetic resonance imaging (MRI) imaging, measuring tumour activity and tumour volume, respectively. Scans were taken at 2 and 7 days post treatment. 
PET and MRI data showed a significant reduction in tumour activity and tumour volume for rats treated with Pac/RAME-beta-CD (at normo- and hyperthermic conditions), compared to the control group. Treatment with TaxolA (R) did not result in a significant reduction of tumour activity and tumour volume. No significant differences between the normo- and hyperthermic conditions were observed for both formulations, indicating that hyperthermia and paclitaxel were not synergistic despite the direct cytotoxic effect of hyperthermia. 
Monitoring tumour growth via PET and MRI indicated that Pac/RAME-beta-CD inclusion complexes had a significantly higher efficacy compared to TaxolA (R) in a rat model for peritoneal carcinomatosis.},
  author       = {Bouquet-Geerardyn, Wim and Deleye, Steven and Staelens, Steven and De Smet, Lieselotte and Van Damme, Nancy and Debergh, Isabelle and Ceelen, Wim and De Vos, Filip and Remon, Jean Paul and Vervaet, Chris},
  issn         = {0724-8741},
  journal      = {PHARMACEUTICAL RESEARCH},
  keyword      = {paclitaxel,hyperthermic intraperitoneal chemotherapy,tumour growth delay,beta-cyclodextrin,PERITONEAL CARCINOMATOSIS,CYTOREDUCTIVE SURGERY,OVARIAN-CANCER,COLORECTAL-CANCER,CREMOPHOR EL,CYCLODEXTRIN COMPLEXES,SYSTEMIC CHEMOTHERAPY,THERMAL ENHANCEMENT,RANDOMIZED-TRIAL,DRUG-DELIVERY},
  language     = {eng},
  number       = {7},
  pages        = {1653--1660},
  title        = {Antitumour efficacy of two paclitaxel formulations for hyperthermic intraperitoneal chemotherapy (HIPEC) in an in vivo rat model},
  url          = {http://dx.doi.org/10.1007/s11095-011-0401-1},
  volume       = {28},
  year         = {2011},
}

Chicago
Bouquet-Geerardyn, Wim, Steven Deleye, Steven Staelens, Lieselotte De Smet, Nancy Van Damme, Isabelle Debergh, Wim Ceelen, Filip De Vos, Jean Paul Remon, and Chris Vervaet. 2011. “Antitumour Efficacy of Two Paclitaxel Formulations for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in an in Vivo Rat Model.” Pharmaceutical Research 28 (7): 1653–1660.
APA
Bouquet-Geerardyn, W., Deleye, S., Staelens, S., De Smet, L., Van Damme, N., Debergh, I., Ceelen, W., et al. (2011). Antitumour efficacy of two paclitaxel formulations for hyperthermic intraperitoneal chemotherapy (HIPEC) in an in vivo rat model. PHARMACEUTICAL RESEARCH, 28(7), 1653–1660.
Vancouver
1.
Bouquet-Geerardyn W, Deleye S, Staelens S, De Smet L, Van Damme N, Debergh I, et al. Antitumour efficacy of two paclitaxel formulations for hyperthermic intraperitoneal chemotherapy (HIPEC) in an in vivo rat model. PHARMACEUTICAL RESEARCH. 2011;28(7):1653–60.
MLA
Bouquet-Geerardyn, Wim, Steven Deleye, Steven Staelens, et al. “Antitumour Efficacy of Two Paclitaxel Formulations for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in an in Vivo Rat Model.” PHARMACEUTICAL RESEARCH 28.7 (2011): 1653–1660. Print.